[Cardiorenal anemia syndrome (review)]

Area of Science:

• Nephrology
• Cardiology
• Hematology

Context:

• Cardiorenal anemia syndrome (CRAS) is a complex condition involving anemia, heart failure (HF), and chronic kidney disease (CKD).
• This pathologic triad significantly impacts patient morbidity and mortality.
• Erythropoietin (EPO) has shown potential benefits in managing anemia within this patient group.

Purpose:

• To explore the role and efficacy of erythropoietin (EPO) in treating anemia in patients with cardiorenal anemia syndrome (CRAS), specifically those with chronic kidney disease (CKD) and heart failure (HF).
• To investigate the optimal target hemoglobin (Hb) levels for EPO therapy in hemodialysis patients with CRAS.
• To assess the impact of EPO treatment on left ventricular function, quality of life, and hospitalization risk.

Summary:

• Research indicates that erythropoietin (EPO) treatment can improve left ventricular function, enhance quality of life, and increase physical tolerance in patients with CRAS.
• EPO therapy has demonstrated success in managing anemia for dialysis patients with CKD, HF, and cardiorenal syndrome type 2.
• European guidelines suggest a target Hb level of no more than 11g/dl for most hemodialysis patients, with pre-dialysis anemia treatment potentially improving quality of life.

Impact:

• EPO treatment offers a potential therapeutic strategy to improve clinical outcomes and quality of life for patients suffering from cardiorenal anemia syndrome.
• Further research into target Hb levels and the precise role of EPO is crucial for optimizing treatment protocols in this vulnerable patient population.
• Understanding the benefits of anemia management, including pre-dialysis treatment, can lead to reduced hospitalizations and better overall patient well-being.